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Study Design: We performed a multicentric,  randomized,  comparative clinical trial. Eligible patients were randomly assigned to 
receive 150 mg of Tolperisone thrice daily or 8 mg of Thiocolchicoside twice daily for 7 days.
Purpose: To assess the efficacy and tolerability of Tolperisone in comparison with Thiocolchicoside in the treatment of acute 
low back pain with spasm of spinal muscles. 
Overview of Literature: No head on clinical trial of Tolperisone with Thiocolchicoside is available and so this study is done.
Methods: The assessment of muscle spasm was made by measuring the finger-to-floor distance (FFD),  articular excursion in 
degrees on performing Lasegue’s maneuver and modified Schober’s test. Assessment of pain on movement and spontaneous 
pain (pain at rest) of the lumbar spine was made with the help of visual analogue scale score. 
Results: The improvement in articular excursion on Lasegue’s maneuver was significantly greater on day 3 (p = 0.017) and 
day 7 (p = 0.0001) with Tolperisone as compared to Thiocolchicoside. The reduction in FFD score was greater on day 7 
(p = 0.0001) with Tolperisone. However there was no significant difference in improvement in Schober’s test score on day 3 
(p = 0.664) and day 7 (p = 0.192). The improvement in pain score at rest and on movement was significantly greater with 
Tolperisone (p = 0.0001). 
Conclusions: Tolperisone is an effective and well tolerated option for treatment of patients with skeletal muscle spasm as-
sociated with pain.
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Introduction 
Generally, the symptoms of most of the uncomplicated 
low back pain (LBP) are managed with short term use of 
non-steroidal inflammatory drugs (NSAIDs) and centrally 
acting skeletal muscle relaxants [1]. Unfortunately NSAIDs 
have unfavorable gastric tolerability profile whereas most of 
the centrally acting muscle relaxants have central nervous 
system side effects such as sedation, dizziness, impairment 
of coordination, mental confusion, weakness, withdrawal 116 / ASJ: Vol. 6, No. 2, 2012
phenomenon or anti-cholinergic adverse effects which re-
sults in non-compliance to treatment and affects ability to 
work [2]. 
The evidence of spinal muscle spasm associated acute 
back pain justifies the use of centrally acting muscle relax-
ant in treatment of acute low back pain. Tolperisone hydro-
chloride, a piperidine derivative, is centrally acting muscle 
relaxant and has been in clinical use for decades in Europe 
and Asia [3]. It acts by inhibiting the pathologic mono- and 
polysynaptic reflex activity in the formation reticularis and 
spinal cord and by stabilizing the nerve membrane [4] in a 
dose dependant manner [2]. It differs from other myotono-
lytic agents due to its pharmacological properties which 
mediate muscle relaxation without concomitant sedation or 
withdrawal phenomenon [3-5]. Unlike other centrally act-
ing skeletal muscle relaxants, it has no substantial affinity to 
adrenergic, cholinergic, dopaminergic or serotonergic recep-
tors in the central nervous system.
Moreover Tolperisone has analgesic activity in humans, 
which could be attributed to its chemical structure, the ter-
tiary aryl amine producing a Lidocaine like activity of stabi-
lizing nerve membranes [2]. Use of central muscle relaxants 
with long duration of action have the risk of neuromuscular 
blockade, hence muscle relaxants with short and intermedi-
ate duration of action like Tolperisone should be preferred 
[1]. 
In several clinical studies Tolperisone has been shown to 
relieve muscle spasms associated with diseases of the spinal 
column or proximal joints [1,6-10]. However, no compara-
tive data on Tolperisone with other centrally acting muscle 
relaxants is available. Thiocolchicoside (TC), a natural 
glycoside is a centrally acting skeletal muscle relaxant used 
in the management of low back pain. TC is slightly more 
effective and scored significantly better than Tizanidine 
(TZ) [11]
 or is at least as effective as TZ in the treatment of 
acute LBP [12]. Hence TC being a commonly used skeletal 
muscle relaxant was used as the comparator in this study. 
This study was conducted with the objective to assess ef-
ficacy and tolerability of Tolperisone in comparison with 
TC in treatment of acute low back pain with spasm of spinal 
muscles. 
Materials and Methods
1. Study design
This was a prospective, multi-centric, randomized, open 
label comparative clinical trial conducted at JJ group of 
Hospitals, Mumbai; AIIMS, New Delhi; Sanjeevani Hospi-
tal, Mumbai; Jubilee Missions Medical College, Thrissur; 
and 3 centers in Kolkata; Kolkata Medical College, Kothari 
Medical Center and Nightingale Hospital. The study proto-
col was approved by the institutional review board at each 
centre, and all patients provided written informed consent. 
The study was conducted according to the International 
Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use–Good 
Clinical Practice Guidelines with strict adherence to the pro-
tocol. 
2. Subject selection criteria
Patients attending the outpatient department were 
screened and assessed according to the specified inclusion 
and exclusion criteria. A total of 250 eligible patients, of ei-
ther sex between 18 to 45 years of age, with spasm of spinal 
muscles with acute or relapsing low back pain, of moderate 
to severe intensity and no finding of severe spinal diseases, 
willing to take medications as directed and come for the 
follow-up were included in the study. 
Patients having other lumbar spinal tract conditions such 
as spondylitis, fracture, cancer, severe arthritis and osteo-
porosis; muscular diseases such as myositis, poliomyositis, 
muscular dystrophia and myotonia; and other severe dis-
eases affecting the neurological or cardiovascular systems, 
liver and kidneys were not enrolled. Patients who had taken 
any form of skeletal muscle relaxant in previous 7 days and 
those with hypersensitivity to any of the ingredients of the 
test formulations were not recruited in the study. Pregnant 
or lactating women or women of child bearing potential not 
following adequate contraceptive measures were excluded.
3. Treatment procedure
Eligible patients were randomized to receive either Tol-
perisone hydrochloride 150 mg thrice daily or TC 8 mg 
twice daily until the patient got relief of muscle spasm and 
pain but not more than 7 days. 
During the trial antacids, H2 blockers or proton pump in-
hibitors were prescribed. Concomitant treatment in the form 
of diclofenac sodium was given to or taken by the patient 
was recorded in the case report form. No other medicines 
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4. Efficacy assessments
Assessment of muscle spasm was carried out on at day 
1 (day of screening and enrolment: visit 1), day 3 (visit 2) 
and day 7 (visit 3) by following procedures: 1) Finger-to-
floor distance (FFD): It was measured by flexion at hip joint 
in standing position. The patient was made to bend down 
as far as possible without bending the knees. The distance 
between the floor and fingertips was measured. The reduc-
tion in the FFD (in cm) on relief of muscle spasm (post drug 
treatment) was measured. 2) Lasegue’s manoeuvre: In this 
test articular excursion of the hip in degrees on performing 
Lasegue’s manoeuvre before inducing pain in supine posi-
tion which involved gradually raising of lower extremity 
by flexing the hip with the knee in extension passively. The 
Laseague’s manoeuvre measured the angle between the 
raised limb and tabletop. The increase in degree of articular 
excursion on relief of spasm (post treatment) was measured. 
3) Modified Schober’s test: The examiner stood behind the 
subject and made three marks; one mark behind lumbosa-
cral junction; a second mark on a spinous process 10 cm 
above first mark (measure to the nearest millimetre) and a 
third mark 5 cm below the first mark. The distance between 
inferior and superior most marks was measured, with “0” at 
inferior mark. Pressing the measuring tape against subject’s 
lower back, having them bend forward keeping the knees 
straight, and the distance between most superior and inferior 
marks at the end of the range of movement (ROM) was re-
corded. The ROM to be recorded as the assessment was the 
difference between the 15 cm and the length measured at 
the end of the motion.
Assessment of spontaneous pain intensity and pain on 
movement was carried out on day 1 (visit 1), day 3 (visit 
2) and day 7 (visit 3) by means of a 10 cm visual analogue 
scale (VAS) as reported by a patient between 0 (no pain) to 
10 (unbearable pain). 
Global Assessment of efficacy of treatment was done at 
the end of the study by investigator and of tolerability by 
patients by means of a 4-point scale (excellent, good, satis-
factory and poor).
5. Statistical analysis
A sample size of 250 completed patients was needed (125 
per treatment group) at a power of 90% and level of signifi-
cance of 95% (α = 0.05) to detect a difference of >20% for 
reduction in FFD distance from baseline on day 5 between 
Tolperisone and TC assuming that Tolperisone achieves a 
reduction of >20% compared to TC. Results are expressed 
as mean and standard deviation (SD) for continuous data, 
and numbers & percentages for discrete data. Comparison 
of two groups was done by Student’s t-test for parametric 
data (FFD, VAS score, articular excursion). Mann-Whitney 
U-test for non-parametric data (rescue drug, global assess-
ment). Pearson’s chi-square test was used for overall assess-
ment of efficacy and tolerability. 
Results
1. Demographics
A total of 289 patients were screened, of which, 250 were 
randomized to either Tolperisone (n = 125) therapy or TC 
(n =  125) and were followed for up to 7 days. Both treat-
ment groups were comparable with respect to demographic 
and baseline characteristics (Table 1). 
The patient compliance for study medication was similar 
in both the study groups. In Tolperisone group 25 patients 
required rescue medication whereas 52 patients required 
rescue medication in TC group. 
Table 1. Demography and baseline characteristics of patients at baseline 
Parameter Tolperisone group Thiocolchicoside group
Mean age (yr) 35.67  ±  7.82   34.68  ±  7.81
Mean weight (kg)    67.24  ±  11.33   65.54  ±  9.45
Mean height (cm) 164.21  ±  10.15 164.91  ±  9.66
Pulse rate (beats/min)  78.25  ±  7.04   78.03  ±  7.47
Systolic blood pressure (mm Hg) 118.91  ±  10.83   120.38  ±  10.82
Diastolic blood pressure (mm Hg) 78.32  ±  7.09     80.17  ±  12.20
Values are presented as mean±standard deviation.118 / ASJ: Vol. 6, No. 2, 2012
1) Efficacy assessment
(1) Assessment of muscle spasm
FFD: Both the medications demonstrated a significant 
effect on the FFD which appeared to be similar. The mean 
change in FFD from the baseline on day 3 and day 7 in 
Tolperisone and TC groups respectively was statistically 
significant. The mean (±SD) distance decreased from 39.72 
(±29.20) cm at baseline to 11.97 (±9.83) cm in Tolperisone 
group and from 42.85 (±28.28) cm at baseline to 16.80 
(±11.77) cm during the treatment with TC at day 7 (Table 
2). On comparison of percentage change of FFD with Tol-
perisone (-32.86%) and TC (-28.71%), was not statistically 
significant on day 3 (p = 0.145), but percentage change of 
FFD with Tolperisone (-69.87%) and TC (-60.80%) was 
statistically significant on day 7 (p = 0.001) (Fig. 1). 
Table 2. Response to Tolperisone and Thiocolchicoside on day 3 and day 7 of treatment on finger-to-floor distance, Laseague’s 
Maneuver score and Modified Schober’s test score
Parameter
Tolperisone group  
(n = 125)
Thiocolchicoside group  
(n = 125) p-value
Finger-to-floor distance (cm)
Baseline   39.72  ±  29.20 42.85  ±  28.28 0.393
Day 3   26.67  ±  21.50 30.55  ±  20.24 0.145
Day 7 11.97  ±  9.83 16.80  ±  11.77 0.001
Laseague’s maneuver score
Baseline   43.82  ±  16.95 43.92  ±  17.49 0.964
Day 3   59.92  ±  13.51 55.53  ±  15.32 0.017
Day 7 73.29  ±  9.85 67.37  ±  14.57 0.001
Modified Schober’s test score (cm)
Baseline   3.47  ±  1.34 3.32  ±  1.33 0.398
Day 3   5.00  ±  1.99 4.89  ±  1.66 0.644
Day 7   6.95  ±  3.08 6.47  ±  2.67 0.192
Values are presented as mean±standard deviation.
Table 3. Effect of Tolperisone and Thiocolchicoside on pain at rest and on movement on day 3 and day 7 post treatment 
Tolperisone  Thiocolchicoside p-value
Pain at rest
Baseline 6.46  ±  1.59 6.54  ±  1.50 0.680
Day 3 4.22  ±  1.51 4.68  ±  1.52 0.018
Day 7 2.19  ±  1.32 2.98  ±  1.33 0.0001
Pain on ovement
Baseline 7.72  ±  1.40 7.73  ±  1.49 0.959
Day 3 5.27  ±  1.69 5.92  ±  1.50 0.003
Day 7 2.99  ±  1.43 3.94  ±  1.46 0.0001
Values are presented as mean ± standard deviation score.
Fig. 1. Percentage change in finger-to-floor distance (cm) 
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(2) Laseague’s manoeuvre score
The muscle relaxant effect of Tolperisone and TC was 
demonstrated by Lasegue’s manoeuvre score. The mean 
Lasegue’s Manoeuvre score with the treatments, Tol-
perisone and TC, significantly improved from the baseline 
on day 3 and day 7 (Table 1). On comparison of percent-
age improvement in the change of Laseague’s Manoeuvre 
Score with Tolperisone (36.74%) and TC (26.43%) on day 
3 (p  =  0.017) was statistically significant (Fig. 2). It was 
also was statistically significant on day 7 (p  =  0.001), Tol-
perisone (67.24%) and TC (53.38%). 
(3) Modified Schober’s test score
The muscle relaxant activity of both the medication 
was demonstrated as observed from the change in mean 
Schober’s Test Score form baseline on day 3 and day 7. The 
improvement in Schober’s Test Score was greater with Tol-
perisone but not statistically significant on day 3 (p = 0.644) 
and day 7 (p = 0.192) (Table 2). Percentage change in mean 
Schober’s Test Score on treatment with Tolperisone and TC 
was observed in both groups is depicted in Fig. 3.
(4) Pain at rest score
The effects of the both medications on spontaneous pain 
are presented in Table 2. The mean (±SD) VAS score de-
creased from 6.46 (±1.59) at the baseline evaluation to 2.19 
(±1.32) at the end of the treatment in patients receiving Tol-
perisone. The improvement in pain at rest score was greater 
with Tolperisone which was significant on day 3 (p = 0.018) 
and day 7 (p = 0.0001) (Table 3). Percentage change in 
mean score for pain at rest with Tolperisone and TC is rep-
resented in Fig. 4.
(5) Pain on movement score
The mean (±SD) pain on movement score improved 
from 7.72 (±1.40) at baseline to 2.99 (±1.43) in Tolperisone 
group and 7.73 (±1.49) at baseline to 3.94 (±1.46) in TC 
group at day 7. The improvement in pain at rest score was 
Fig. 2. Change in mean Laseague’s manoeuvre score with 
Tolperisone and Thiocolchicoside.
Fig. 3. Percentage change in mean Schober’s test score on 
treatment with Tolperisone and Thiocolchicoside.
Fig. 5. Percentage change in mean pain score on movement 
with Tolperisone and Thiocolchicoside.
Fig. 4. Percentage change in mean pain at rest with Tol-
perisone and Thiocolchicoside.120 / ASJ: Vol. 6, No. 2, 2012
greater with Tolperisone on day 3 (p  =  0.003) and day 7 
(p  =  0.0001) which was statistically significant (Table 3). 
Percentage change in mean pain score at rest movement 
with Tolperisone and TC is shown in Fig. 5.
(6) Rescue medication 
The rescue medication in the form of diclofenac sodium 
was provided to 16 patients in the Tolperisone group and 39 
patients in TC group.
(7) Global efficacy assessment by physicians
As per the assessment by physician Tolperisone produced 
good to excellent efficacy in 90.25% of patients where as 
thiocolchiocoside produced good to excellent efficacy in 
73.33 % of patients (Fig. 6). 
2. Safety and tolerability assessments
The evaluation of the adverse drug reactions occurring 
during the trial showed a significant tolerability in favour of 
Tolperisone. As per the global assessment by patients Tol-
perisone produced good to excellent efficacy in 89.9% of 
patients where as thiocolchiocoside produced good to excel-
lent efficacy in 52.5% of patients (Fig. 7). 
Only 7 patients out of 125 suffered from side effects in 
Tolperisone group compared to 14 patients out of 125 who 
suffered from side effects in Thiocolchicocide group. The 
adverse events experienced with Tolperisone were loose 
motion (n = 1), nausea (n = 2), giddiness (n = 2), abdominal 
pain (n=1), itching (n=1) and with TC were loose motion 
(n  =  8), skin rash (n = 1) nausea (n = 1), giddiness (n  =  4). 
All adverse events were of mild intensity and resolved 
without any intervention. They were reported on day 3 and 
resolved on day 7 of trial. 
Discussion
Tolperisone has been evaluated and found to be effective 
for the treatment of several musculoskeletal disorders like, 
cervicobrachial myofascial pain syndrome, post-stroke spas-
ticity, back pain, multiple sclerosis, vertebrogenic algesic 
syndromes, neuroleptic syndrome, neurolathyrism, neuro-
sensory hypoacusis, painful reflex muscle spasm, muscular 
and vascular complaints accompanying climacterics. It is 
also used as an adjuvant to complex therapy, in 300 to 450 
mg daily doses, for the treatment of locomotor diseases ac-
companied by muscular hypertonia, muscular spasticity, and 
contracture [2].
Tolperisone, a centrally acting muscle relaxant (CMR) 
free from side effects, first described by Nador and Porszasz 
in 1958, is a clinically useful drug for relieving spasticities 
of neurological origin and muscle spasms associated with 
painful locomotor diseases. Its first description classified it 
as an antinicotinic drug based on the fact that it effectively 
inhibited nicotine induced lethality. Nevertheless, it also in-
hibited convulsions evoked by electroshock, pentylenetetra-
zole or strychnine. Its most characteristic effect, however, is 
potent inhibition of mono and polysynaptic spinal reflexes, 
and Ono et al. [13] reported that a “membrane stabilizing” 
effect may underlie its pharmacological actions. Tolperisone 
acts as an acute blocker of voltage dependent sodium chan-
nels. 
Several randomized controlled clinical trials have demon-
strated that Tolperisone has superior efficacy as compared 
to placebo in the treatment of spastic hypertonia following 
cerebral stroke [6-8]. In this indication an individual dose ti-
tration which may exceed the recommended maximum dose 
of 450 mg daily results in optimized therapeutic benefit [6-
8].  
Fig. 6. Global efficacy assessment by physician (% of pa-
tients) with Tolperisone and thiocolchicoside. 
Fig. 7. Global assessment of tolerability by patients (% of 
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The skeletal muscle relaxant and analgesic activity of 
Tolperisone has been evidenced in experimental jaw-muscle 
pain [9]. When used as prophylactic, Tolperisone reduced 
isometric force in post-exercise muscle soreness [5]. 
Adverse events experienced were less with Tolperisone as 
compared to placebo and were mostly of mild-to-moderate 
intensity. Tolperisone has a good tolerability and no with-
drawals caused by adverse events with Tolperisone [6-9,11]. 
 Single and repeated doses of Tolperisone hydrochloride 
150 mg showed that Tolperisone hydrochloride, although 
being a centrally active muscle relaxant, does not cause any 
sedation and does not impair reaction times [4]. 
Skeletal muscle relaxant activity of oral Tolperisone has 
been evaluated in a prospective, randomized, double-blind, 
placebo-controlled in the treatment of painful reflex muscle 
spasm associated with diseases of the spinal column or 
proximal joints. In this study a total of 138 patients, aged 
between 20 and 75 years, were enrolled in 8 rehabilitation 
centers. Patients were randomized to receive either 300 mg 
Tolperisone hydrochloride or placebo for a period of 21 
days. Both treatment groups recovered during the 3 weeks 
rehabilitation program. However, Tolperisone hydrochloride 
proved to be significantly superior to placebo treatment. 
(p  =  0.03) [2]. 
TC, a natural glycoside is a centrally acting skeletal 
muscle relaxant used in the management of low back pain. 
In clinical trial conducted in Indian population, it was found 
that Tolperisone was slightly more effective and scored 
significantly better than TZ [10].
 Another study showed that 
TC was at least as effective as TZ in the treatment of acute 
LBP, while it appears devoid of any sedative effect in con-
trast to TZ [12].
 Hence TC being a commonly used skeletal 
muscle relaxant was used as the comparator in this study. 
Our results demonstrate that Tolperisone is an effec-
tive muscle relaxant agent with efficacy similar to that of 
other compounds, such as TC, which are currently used in 
the management of low back pain due to a spinal muscles 
spasm. The results to this study showed that Tolperisone 
150 mg provides a better clinical response rates and symp-
tom control over TC 8 mg in patients with acute low back 
pain with spinal muscle spam. This could be explained by 
the fact that Tolperisone acts by more than one mechanism: 
inhibiting the pathologic mono- and polysynaptic reflex 
activity in the formation reticularis and spinal cord and by 
stabilizing the nerve membrane. Moreover Tolperisone has 
analgesic activity in humans, which could be attributed to 
its chemical structure, the tertiary aryl amine producing a 
Lidocaine like activity of stabilizing nerve membranes.
The score differences in Laseague’s maneuver, pain at rest 
for both day 3 and day 7 and pain on movement for day 7, 
showed significantly better results in Tolperisone group. Oth-
er muscle spasm assessment parameters also showed better 
improvement in Tolperisone; however not statistically signif-
icant for both day 3 and day 7. The limitations of the study 
may be was short follow-up and absence of a control group. 
The need of rescue medication was significantly greater in 
TC group than that of in Tolperisone group. Global impres-
sion on efficacy by doctors and tolerability by patients show 
significant differences at the end of the study (p < 0.001) 
the adverse events profile was similar to that documented in 
earlier studies. 
Another consistent advantage of Tolperisone over TC and 
other muscle relaxant agents is represented by tolerance; 
in this study, the adverse events were mild to moderate in 
intensity. On global assessment of tolerability 91.87% of the 
patients graded Tolperisone as good to excellent. This could 
be because unlike other centrally acting skeletal muscle 
relaxants, it has no substantial affinity to adrenergic, cholin-
ergic, dopaminergic or serotonergic receptors in the central 
nervous system.
Conclusions 
Tolperisone is an effective skeletal muscle relaxant agent 
with efficacy similar to TC and relatively better tolerated 
option for treatment of patients with low back pain associ-
ated with muscle spasm.
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